Genentech Licenses A Cancer Metabolism Program From Forma, With Option To Buy
This article was originally published in The Pink Sheet Daily
The Roche-owned biotech licensed a novel oncology target from the startup, but could take outright possession of the program - with a payout for VCs.
You may also be interested in...
Forma Therapeutics has already convinced several big industry partners its discovery engine will yield oncology candidates in emerging areas of research. Now it wants to find academic groups to help feed its engine, all while the resurgent biotech IPO market might make its unusual structure superfluous.
While the single compound biotech is still the dominant business model, some biotechs are exploring less traditional strategies that will make them sustainable in rough economic times.
For $95 million guaranteed, Genentech gains rights to broad research in the emerging field over a three-year period, as well as an option to acquire the start-up outright.